Back to Search
Start Over
[CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm].
- Source :
-
Der Internist [Internist (Berl)] 2021 Jun; Vol. 62 (6), pp. 589-596. Date of Electronic Publication: 2021 Jun 21. - Publication Year :
- 2021
-
Abstract
- Following the first demonstration of efficacy of anti-CD19-directed chimeric antigen receptor (CAR) T cells in a patient with relapsed chronic lymphocytic leukemia (CLL) in 2011, pivotal studies for this innovative therapy were initially conducted in multiple relapsed or refractory (r/r) childhood and young adult acute B‑cell leukemia and in aggressive adult B‑cell lymphoma. The studies demonstrated efficacy even in chemotherapy-refractory disease, resulting in the first approval of autologous and genetically engineered T cells for the treatment of r/r B‑cell acute lymphoblastic leukemia (B-ALL) in the US for the product tisagenlecleucel (Kymriah®, Novartis) back in 2018. Approval for the treatment of r/r aggressive B‑cell lymphoma followed shortly thereafter for tisagenlecleucel and axicabtagene ciloleucel (Yescarta, Kite/Gilead). This review focuses on the treatment of aggressive B‑cell lymphoma and other CD19 positive B‑cell lymphomas by summarizing the study results of clinically tested CAR T cells, discussing possible resistance mechanisms, and providing an outlook on ongoing studies with new target antigens for the treatment of B‑cell lymphomas.
Details
- Language :
- German
- ISSN :
- 1432-1289
- Volume :
- 62
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Der Internist
- Publication Type :
- Academic Journal
- Accession number :
- 34152469
- Full Text :
- https://doi.org/10.1007/s00108-021-01056-3